CHARMAINE BYRD: Open Payments
NPI 1669073474 · TUCKER, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$820 in 44 payments from 9 companies in 2025. Trend: 2023 $205 · 2024 $729 · 2025 $820
Food & beverage: $820
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $184 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $162 |
| ABBVIE INC. | 7 | $161 |
| Neurocrine BioSciences, Inc. | 11 | $156 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Indivior Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, AUSTEDO XR, Auvelity, LYBALVI, SUBLOCADE.
Industry payments across GA — which companies pay providers there.
